Tag Archives: amgn

Valeant Subpoenaed By Federal Prosecutors On Pricing

Valeant Pharmaceuticals (VRX) late Wednesday said it has received subpoenas from U.S. Attorneys in Massachusetts and the Southern District of New York related to drug pricing and how it helps patients pay for drugs. It comes as Valeant and a slew of biotechs such as Biogen (BIIB), Gilead Sciences (GILD), Amgen (AMGN) and Celgene (CELG). Valeant said in a statement: “Most of the materials requested by the subpoenas relate to documents with respect

After-Hours Action: JetBlue, Amgen, Medtronic

Here’s a quick rundown of Monday’s after-the-close action: JetBlue Airways (JBLU) said Sept. traffic jumped 13.3% while capacity increased 13.1%. Load factor rose 0.2 percentage point to 81.1%. Shares were down 2.1% after the closing bell. Amgen (AMGN) issued positive trial data for its romosozumab, which showed increased estimated bone strength at the spine and hip in postmenopausal women with low bone mass. Shares edged up 0.5% late. Silicon

Regeneron Stock Pops But Hits Resistance At 50-Day

Regeneron Pharmaceuticals (REGN) popped in the stock market today, but shares are hitting resistance at a key level. The biotech now faces less competition for its cholesterol drug, as Eli Lilly (LLY) is discontinuing development of its heart-disease treatment, which RBC Capital Markets notes is a big benefit for Regeneron and its larger peer Amgen (AMGN). Regeneron gapped up 5.2% in heavy volume on Monday. But the stock looks to be finding